Pacific Biosciences of California, Inc. Stock News

New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christian O. Henry - President, CEO & Director James R.

PACB Sales Up 11%

MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:

The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON , July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a new laboratory test service intended to provide insights into genetic causes of ataxi...

Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations

New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencing New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencing